Tag: Studies

A Single Dose of Cannabidiol (CBD) Reduces Blood Pressure, Study Finds

Oral CBD administration is associated with reduced blood pressure in healthy volunteers, according to clinical trial data published online in the Journal of Clinical Investigation.

Investigators from the University of Nottingham in the United Kingdom assessed the effects of a single oral dose of 600 mg of CBD extract versus placebo in nine male subjects.

Cannabidiol administration reduced resting systolic blood pressure and stroke volume (the amount of blood pumped by the left ventricle of the heart in one contraction).

Compared to placebo, CBD intake was associated with reduced BP levels following exercise and in response to stress.

Increased heart rate was observed following CBD administration, but no “adverse events” were reported by participants either during or following the study sessions.

Authors concluded:

“Our data show that a single dose of CBD reduces resting blood pressure and the blood pressure response to stress, particularly cold stress, and especially in the post-test periods. This may reflect the anxiolytic and analgesic effects of CBD, as well as any potential direct cardiovascular effects. … Further research is also required to establish whether CBD has any role in the treatment of cardiovascular disorders such as a hypertension.”

Full text of the study, “A single dose of cannabisiol reduces blood pressure in healthy volunteers in a randomized crossover study,” is online here.

Tags: , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Marijuana Infused Tea is Effective in Treating Chronic Pain, Study Finds

PARMA, ITALY — Oral cannabis administration is safe and effective for the treatment of chronic pain conditions, according to clinical data published in the Journal of Pain Research.

Italian researchers conducted a retrospective case series analysis assessing the use of cannabinoids for intractable pain in a cohort of over 600 patients. Study subjects were typically over the age of 60 and consumed cannabinoids via infused tea.

Researchers reported that no subjects in the study complained of severe side effects, and that relatively few patients discontinued cannabis treatment.

They concluded: “[I]t can be stated that the treatment seems to be effective and safe in the majority of patients.”

In 2015, the Italian government authorized the use of cannabis to treat several debilitating conditions, including chronic pain, glaucoma, Tourette syndrome, multiple sclerosis, HIV/AIDS, and certain types of epilepsy.

In January, an extensive literature review by the US National Academy of Sciences acknowledged that “conclusive or substantial evidence” exists for cannabis’ efficacy in patients suffering from chronic pain, among other conditions.

Full text of the study, “Cannabis and intractable chronic pain: an explorative retrospective analysis of Italian cohort of 614 patients,” appears in the Journal of Pain Research.

Tags: , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Medical Marijuana Laws Don’t Lead to More People Smoking Weed

A medical cannabis patient’s supply of medicine in their home. (Sonya Yruel/Drug Policy Alliance)

The enactment of medical marijuana laws is not associated with increased rates of problematic cannabis use, according to data published online in the journal Addiction.

Columbia University investigators assessed cannabis use trends in states in the years following the passage of medicalization. They reported “no significant change in the prevalence of past-month marijuana use among adolescents or young adults (those ages 18 to 25)” following legalization.

They also found no evidence of increased cannabis abuse or dependence by either young people or adults. States with largely unregulated medical programs were associated with increased self-reported use by adults age 26 and older, but states with stricter programs were not.

The study’s findings are consistent with those of numerous other papers reporting no uptick in youth marijuana use or abuse following medical marijuana regulation, including those here, here, here, here, here, and here. The findings contradict those of a recent, widely publicized paper in JAMA Psychiatry which speculated that medical marijuana laws may increase the prevalence of cannabis use disorder among adults.

An abstract of the study, “Loose regulation of medical marijuana programs associated with higher rates of adult marijuana use but not cannabis use disorder,” is online here.

Tags: , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Cannabis Extracts Associated With Reduced ADHD Symptoms

LONDON — The administration of whole-plant cannabis extracts is associated with improvements in cognition and behavior in subjects with Attention Deficit Hyperactivity Disorder (ADHD), according to clinical trial data published online ahead of print in the journal European Neuropsychopharmacology.

British scientists conducted a randomized, placebo-controlled trial evaluating the efficacy of cannabis extracts in 30 adults with ADHD.

Treatment was associated “with a nominally significant improvement in hyperactivity/impulsivity and a trend for improvement in inattention. There were further indications for improvement in activity and cognitive performance, and emotional lability.”

Investigators concluded:

“ADHD may represent a subgroup of individuals that gain cognitive enhancement and reduction of ADHD symptoms from the use of cannabinoids. These findings provide preliminary evidence using an experimental design for the self-medication hypothesis of cannabis use in ADHD; and support the need for further research into the effects of cannabinoids on ADHD symptoms and impairments.”

Full text of the study, “Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial,” appears in European Neuropsychopharmacology.

Tags: , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Cannabidiol (CBD) Found to Reduce Seizure Frequency in Phase III Trial

The oral administration of CBD (cannabidiol) reduces seizure frequency in children with intractable epilepsy, according to placebo-controlled, randomized trial data published in The New England Journal of Medicine.

A team of investigators from the United States and England evaluated the effects of pharmaceutically standardized cannabidiol extracts (aka Epidiolex) versus placebo in 120 children and young adults with treatment-resistant Dravet syndrome.

They reported:

“The median frequency of convulsive seizures per month decreased from 12.4 to 5.9 with cannabidiol, as compared with a decrease from 14.9 to 14.1 with placebo.”

In April, researchers announced similar results in patients with Lennox-Gastaut syndrome, another severe form of epilepsy.

The lead author of the new study, Dr. Orrin Devinsky, director of the Comprehensive Epilepsy Center at New York University Langone Medical Center said that the findings warrant the immediate rescheduling of marijuana under federal law. “Cannabis is approved in 20 countries for spasms in multiple sclerosis,” he said. “So to say there’s no evidence of efficacy is simply untrue. … They have to de-schedule this drug. It’s just not fair to the research and clinical communities, or to the patients. It’s medieval.”

The manufacturer of Epidiolex, British biotechnology company GW Pharmaceuticals, is seeking FDA approval for its product for the treatment of severe seizure disorders.

Full text of the study, “Trial of cannabidiol for drug resistant seizures in the Dravet syndrome,” appears in The New England Journal of Medicine.

Additional information regarding the efficacy of cannabis and cannabinoids in the treatment of epilepsy is available online from NORML.

Tags: , , , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Marijuana Does Not Lead to an Increase in Psychotic Symptoms

PHILADELPHIA, PA — There exists “minimal evidence” in support of an association between cannabis use by itself and the onset of psychotic symptoms in young people, according to data published online ahead of print in the Journal of Adolescent Health.

Investigators from the University of Pennsylvania, Department of Psychiatry assessed the relationship between drug use and the onset of psychotic symptoms in a cohort of 4,171 young people ages 14 to 21. Authors reported that “neither frequent nor early cannabis use predicted increased odds of psychosis spectrum classification” after researchers adjusted for potential confounders (e.g., concurrent use of other substances, comorbid psychopathology, and trauma exposure).

They concluded:

“Overall, we found minimal evidence for associations between cannabis use by itself and psychosis spectrum symptoms.”

The findings are similar to those of a 2015 longitudinal study reporting that early-onset cannabis use is not positively associated with a greater risk of psychosis or other mental health disorders in mid-life.

A 2016 literature review published in the journal Current Psychiatry Reports concluded that cannabis use likely does not cause the psychosis, but rather, that subjects susceptible to the disorder may be more likely to engage in habitual use of the substance.

Full text of the study, “Cannabis use, polysubstance use, and psychosis spectrum symptoms in a community-based sample of U.S. youth,” appears in the Journal of Adolescent Health.

Tags: , , , , , , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Cannabis Use in Australia Has Dropped Significantly. Why?

Cannabis use declined significantly in Australia between 2001 and 2013, according to a new report out of the University of New South Wales. But while the use-rate data seem solid, the underlying reasons for the decline are harder to pin down.

Between 2001 and 2013, consumption fell dramatically, especially among  young people. Among individuals aged 14 to 19, past-year use dropped from 24.4% to 14.8%. Among those in their 20s, past-year use declined from 29.1% to 20.8%. The only recorded uptick was a slight rise in consumption among those in their 40s.

(Image via "Trends in Drug Use and Related Harms in Australia, 2001 to 2013," University of New South Wales. PDF)(Image via “Trends in Drug Use and Related Harms in Australia, 2001 to 2013,” University of New South Wales. PDF)

A combination of five significant factors may be contributing to the phenomenon, according to a review paper published in Drug & Alcohol Review. The piece, by University of New South Wales academics Alison Ritter and Oluwadamisola Sotade, calls for more comprehensive research into the reasons for the decline in cannabis use in Australia.

“We have known for some time about the declines,” said Ritter, who also authored the report itself. “This was more about trying to start to think about why.”

RELATED STORY

Here’s Why Cannabis Legalization Doesn’t Lead to Higher Teen Use Rates

Ritter and Sotade identified various changes in attitude, regulation, supply, and complementary drug use as factors that might help explain the decline, as well as an “increasing focus on healthy lifestyles.”

To better understand such factors, the authors argue, “A new research agenda is required, with a multidisciplinary focus including regulation theory, economics and econometric techniques, comparative policy analysis methods, and sociology and cultural analysis such that the plausible reasons can be empirically tested.”

Will Australia’s Medical Cannabis Law Impact Broader Use?

“It’s very hard to speculate on this,” Ritter told Leafly, “but research published from the USA after their experience with medicinal cannabis suggests that rates of cannabis use in young people [has] not increased in association with medicinal cannabis.”

RELATED STORY

CDC Says Teen Cannabis Use Dropping as More States Legalize

“There is conflicting evidence about cannabis use amongst adults,” she added. “Some studies do show a trend to increasing cannabis use, others do not. There does appear to be evidence of an increase in cannabis use disorders.”

Among medical marijuana states in the US, Ritter said less-regulated systems may be more  likely to contribute to a rise in nonmedical use. “The effects depend on the kinds of medicinal cannabis programs” in place, she said.

RELATED STORY

Another Study Shows Cannabis Legalization Does Not Increase Underage Access

What About Decriminalization?

Ritter noted “there has always been very strong support for [decriminalization] in Australia,”  pointing  out that every state has some style of decriminalization law on the books. In a paper published last year, Ritter and other University of New South Wales academics published data on the effects of decriminalization.

The research evidence indicates that decriminalisation of drug use:

  • Reduces the costs to society, especially the criminal justice system costs
  • Reduces social costs to individuals, including improving employment prospects
  • Does not increase drug use
  • Does not increase other crime
  • May, in some forms, increase the numbers of people who have contact with the criminal justice system (net widening)

Evidence that decriminalization doesn’t result in increased drug use is not, of course, the same as a finding that it results in decreased drug use. Nevertheless, it’s relevant data to consider as communities weigh how further decriminalization measures could affect cannabis use rates.


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Washington State University Needs Paid Volunteers to Smoke Marijuana for Research Study

PULLMAN, WA — Are you 21 or older, live in Washington, and want to get paid to smoke pot as part of a research study?

Researchers at Washington State University are working to develop a breathalyzer to detect marijuana use, and are seeking paid volunteers to participate.

Volunteers will earn $30 for their first hour of participation in the study, and $10 per hour for every additional hour they take part.

Researchers will not be providing marijuana to participants, however, because providing cannabis to volunteers would be in violation of federal law, putting the University at risk for a loss of federal funding.

Volunteers must be at least 21 years old to participate in the study under Washington state law.

After a preliminary blood test and mouth swab, volunteers will be responsible for purchasing marijuana of their choice from any licensed Washington state retail marijuana store and smoke it in the privacy of their own home.

After smoking the marijuana, taxi cabs will transport volunteers from their homes to a hospital for additional testing to prevent any participant from driving under the influence.

Participants will also be encouraged to take part in a standard field sobriety test conducted by local law enforcement as part of the study.

Currently, the most common way to test a marijuana user’s impairment is through a blood test, and arbitrary per se limits to how much tetrahydrocannabinol (THC) have been a heavily debated point of contention as marijuana laws are loosened in the United States.

While there is no current standard for what constitutes driving under the influence of marijuana, under Washington state law drivers with five nanograms of active THC in their bloodstream can be prosecuted for a DUI.

A study conducted last year by the American Automobile Association (AAA) Foundation for Traffic Safety determined that per se limits for THC are arbitrary and can not be scientifically reported.  A federally sponsored study conducted in 2015 determined that drivers who tested positive for THC in their blood were no more likely to be involved in car crashes than drug-free drivers.

The study will take place the last two weeks of May and continue through the first two weeks of June. For residents of Pullman, Washington who meet the qualifications of the study and wish to participate, contact Nathan Weller at (509)-432-1943 or by email at nathan_weller@hotmail.com.

Tags: , , , , , , , , , , , , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Inhaled Cannabis Controls Tics in Patients With Tourette’s Syndrome

Sonya Yruel/Drug Policy Alliance

Inhaled cannabis is effective and well-tolerated in patients with Tourette’s Syndrome, according to clinical data published online ahead of print in the Journal of Neuropsychiatry and Clinical Neuroscience.

A team of researchers at the University of Toronto retrospectively assessed the safety and efficacy of inhaled cannabis in 19 TS patients.

Researchers reported, “All study participants experienced clinically significant symptom relief,” including including reductions in obsessive-compulsive symptoms, impulsivity, anxiety, irritability, and rage outbursts. Eighteen of 19 patients experienced decreased tic severity.

Cannabis was “generally well tolerated” by study subjects.

They concluded:

“Overall, these study participants experienced substantial improvements in their symptoms. This is particularly striking given that almost all participants had failed at least one anti-tic medication trial. … In conclusion, cannabis seems to be a promising treatment option for tics and associated symptoms.”

Placebo controlled data has previously determined that oral THC dosing also improves tics and obsessive-compulsive behavior in TS patients. However, patients utilizing inhaled cannabis have generally shown greater overall improvement.

An abstract of the study, “Preliminary evidence on cannabis effectiveness and tolerability for adults with Tourette Syndrome,” is online here.

Tags: , ,


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.

Study: Marijuana Use Linked to Lower Prevalence of Fatty Liver Disease

Study: Marijuana Use Linked to Lower Prevalence of Fatty Liver Disease | NORML

LOWELL, MA — Subjects who consume cannabis are significantly less likely to suffer from non-alcoholic fatty liver disease (NAFLD) as compared to those who do not, according to population-based case-control data published in the journal PLOS One. Non-alcoholic fatty liver disease is the most prevalent form of liver disease in humans, affecting an estimated 80 […]

Study: Marijuana Use Linked to Lower Prevalence of Fatty Liver Disease | The Daily Chronic


Thank you for visiting MDMMCC.com, the premier Medical Marijuana Certification Center in Maryland. Our Mission at the Maryland Medical Marijuana Certification Clinics (MDMMCC) is to provide the certification necessary for qualified patients to obtain Medical Marijuana in compliance with the Maryland Medical Marijuana Laws in the State of Maryland.  MDMMCC will have offices open throughout Maryland.